“Jefferies Backs D-Wave Quantum (QBTS) Despite Mixed Q1 Earnings, Solid Bookings”
Catching the stride in quantum computing, D-Wave Quantum outperforms with its dual approach technology, affirming a "Buy" rating from Jefferies. Despite mixed financial performance, surges in bookings and robust future business propositions signal promising growth. With agitation in the tangible yield, watch as D-Wave Quantum unscrambles its earnings conundrum. Read more
Read More
“Strong YUTREPIA Results Prompts Jefferies to Upgrade Liquidia (NASDAQ: LQDA)”
Jefferies' analyst predicts a bullish future for biotech company Liquidia (NASDAQ: LQDA), raising the price target from $57.00 to $60.00. This follows Liquidia's groundbreaking success with pulmonary disease drug, YUTREPIA, its remarkable Q1 2026 revenue of $133 million, and a triumphant financial turnaround of profitability for three consecutive quarters. Read more
Read More
“Lyft’s Price Target Slashed Amid Uncertain Q1 Outcomes (NASDAQ:LYFT)”
Canaccord Genuity revises Lyft's price target amidst mixed Q1 results. Despite missing EPS estimates, Lyft exhibits robust growth through key metrics including a 13.8% revenue increase and rise in active riders. This strong operational performance indicates promising potential, even amid lowered price targets. Read more
Read More